Amgen has finally put an end to weeks of rumours and speculations
by admitting its plans to slash 12-14 per cent of its workforce to
offset the recent difficulties it has been facing with the sales of
its anaemia blockbusters.
A European regulatory committee has recommended the approval of
three generic versions of Johnson & Johnson's (J&J) anaemia
blockbuster Eprex in what could lead to the market launch of new
"biosimilars" by the...
Swiss drug major Roche is facing a delay in bringing its EPO drug
Mircera (continuous erythropoietin receptor activator) to market in
the US after the Food and Drug Administration sent it an
'approvable' notice for the product.
The decision of the US Supreme Court not to hear Amgen's appeal in
a patent infringement case against Sanofi-Aventis and Shire,
involving the anaemia drug Epogen (epoetin alfa), may weaken
Amgen's position in keeping another...
The latest data on cases of antibody-mediated pure red cell aplasia
associated with Johnson & Johnson subsidiary Janssen-Cilag's
erythropoietin product Eprex/Erypo (epoetin alfa) have suggested
that measures put in place...